IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00488839
• Other study ID #: IPX056-B06-03
• Secondary ID: 2007-000236-16
• Status: Completed
• Phase: Phase 3
• Start date: June 2007
• Est. completion date: May 2008

Study information

• Verified date: February 2017
• Source: Impax Laboratories, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on spasticity. Lastly, this study will determine how long IPX056 affects spasticity.

Description:

The primary objective of this study is to demonstrate that IPX056 reduces spasticity, measured by Ashworth score, in subjects with multiple sclerosis (MS). This study will also (1) assess the correlation between pharmacokinetic (PK) and pharmacodynamic (PD) endpoints (Ashworth score), and (2) quantify the duration of pharmacodynamic effects for IPX056 as well as marketed baclofen tablet in subjects with Multiple Sclerosis (MS) after a single dose. Additionally, the efficacy parameters, including Multiple Sclerosis Impact Scale (MSIS)-29, spasm frequency and nighttime awakening score, spasticity control, morning stiffness, and Global Assessment of Efficacy and Tolerability, will be assessed during open-label extension period. The safety of IPX056 will be monitored throughout the study.

This study consists of 2 parts: Part I (Screening Visit & Visit 1) of the study is a single-dose, double-blind, randomized, placebo- and active comparator-controlled, parallel group design containing a single 12 hour PK/PD evaluation period. Part II is an optional, approximately 9-week open-label extension study and will start during Visit 1, immediately after Visit 1 PK/PD procedures are completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female at least 18 years old. If female and of childbearing potential, continuing to practice and willing to continue throughout the study with appropriate contraceptives (defined as oral, injected, or implanted contraceptives, or barrier contraception). The subject must agree to take every precaution to ensure that pregnancy will not occur during the study. Female subjects of childbearing potential must have a negative urine pregnancy test immediately prior to study entry.

• Able to understand and willing to voluntarily sign an informed consent form (ICF) and an Authorization to Use and Disclose Protected Health Information form (as required by the Health Insurance Portability and Accountability Act {HIPAA} legislation, if appropriate for the region) prior to the performance of any study-specific procedures.

• Has a negative urine drug screen at screening visit.

• Has Definite multiple sclerosis by Poser or McDonald Criteria.

• Expanded Disability Status Scale (EDSS) rating between 3.0-8.0

• Has a normal ECG and a blood pressure <160/95 mmHg (systolic)/diastolic) at screening, measured in the sitting position after approximately 5 minutes of quiet rest.

• If the subject has a history of or presence of clinically significant peptic ulcers, liver disease, diabetes mellitus, hypertension or heart disease, the subject must be on a stable treatment regimen for a minimum of 3 months prior to Screening Visit

• Wiling to wash out current medication with anti-spasticity activities, including but not limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam, gabapentin, and tizanidine.

• Ashworth score of 2 or more for at least one of the three lower extremity muscle groups (hip adductor, knee flexor, knee extensor) in the most affected limb and a total minimum score of 6 for four muscle groups (the above three plus plantar flexor) on both limbs (maximum total score is 32) during screening visit and at pre-dose during PK/PD Visit 1.

• Able and willing to comply with the protocol, including availability for all scheduled clinic visits

Exclusion Criteria:

• If female, the subject is:

1. pregnant; or planning to become pregnant; or

2. breastfeeding; or

3. a woman of child-bearing potential (defined as post menarche and biologically capable of becoming pregnant [i.e., not surgically sterile]) who is engaged in active heterosexual relations and is not using a barrier or hormonal form of birth control (i.e. oral, injected, or implanted contraceptives).

• History of allergic or severe intolerance to baclofen.

• Did not respond to previous baclofen treatment in any formulation.

• Treated with intrathecal baclofen within the previous 6 months prior to the Screening Visit.

• Has experienced an exacerbation of MS within 6 months prior to the Screening Visit.

• Symptomatic urinary tract infection (UTI) within 4 weeks prior to the Screening Visit and more than two (2) UTI incidents within the last 6 months.

• Serum creatinine level = 2 x ULN (upper limit of normal reference range) at the Screening Visit or requires dialysis.

• Liver enzyme values = 2 x ULN (upper limit of normal reference range) at the Screening Visit.

• Uncontrolled peptic ulcers, liver disease, diabetes mellitus, bladder sphincter hypertonia, hypertension or heart disease.

• History of seizure or epilepsy, or is currently taking an anti-convulsant for treatment or control of seizure.

• Concomitant neurologic conditions causing spasticity (e.g. stroke, cerebral palsy, traumatic brain injury) or rigidity (e.g. Parkinson's disease).

• Any medical condition, including psychiatric disease, which would interfere with the interpretation of the study results, the conduct of the study, or the safety of the subject.

• Currently taking antipsychotics, CNS depressants or CNS depression producing medications (including alcohol, sedating antihistamines, barbiturates, narcotics, and phenothiazines), monoamine oxidase inhibitors (MAOI, including furazolidone, procarbazine, selegiline, and tranylcypromine), and tricyclics.

• Unable or unwilling to wash out current anti-spasticity medications, including but not limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam, gabapentin, and/or tizanidine for Day 1, Visit 1, procedures. However, these medications will be allowed during open label study.

• Unable or unwilling to participate 12-hour PK/PD procedures during Visit 1.

• Treated with Botulinum Toxin Type A or B within the previous 6 months, or Phenol or therapeutic alcohol nerve block within 12 months prior to the Screening Visit.

• History of alcohol abuse or use of recreational drugs within 12 months prior to the Screening Visit.

• Has received an investigational drug or device within 30 days prior to the Screening Visit.

• Has clinically significant limitation of passive range of motion around any of the joints being assessed in this study.

• Has had major surgery within 3 months prior to Screening visit that may affect spasticity assessments such as abdominal surgery, back surgery, lower leg and knee surgeries.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Muscle Spasticity
• Sclerosis

Intervention

Drug:
• IPX056 20 mg
IPX056 Extended Release capsule containing 20 mg baclofen
• IPX056 40 mg
IPX056 Extended Release capsule containing 40 mg baclofen
• Encapsulated Baclofen 20 mg
Baclofen 20mg tablet was encapsulated for blinding.
• Placebo Baclofen Tablet
Placebo capsule encapsulated placebo Baclofen tablet
• IPX056 10 mg
IPX056 Extended Release capsule containing 10 mg baclofen
• IPX056 30 mg
IPX056 Extended Release capsule containing 30 mg baclofen
• IPX056 35 mg
IPX056 Extended Release capsule containing 35 mg baclofen
• Placebo IPX056 20 mg
Placebo capsule for IPX056 20 mg
• Placebo IPX056 40 mg
Placebo capsule for IPX056 40 mg

Locations

Country	Name	City	State
Canada	Foothills Medical Centre, MS Clinic, SSB	Calgary
Canada	Montreal Neurological Institute and Hospital	Montreal	Quebec
Estonia	West-Tallinn Central Hospital	Tallinn
Latvia	Vecmilgravis Hospital, Latvian Maritime Medicine Center	Riga
Ukraine	Chernihiv Regional Hospital Department of Neurology	Chernihiv
Ukraine	Neurology and Neurosurgery Dpt., Postgraduation training faculty, Dnipropetrovsk State medical Academy	Dnipropetrovsk
Ukraine	Institue of Neruology, Psychiatry and Narcology of AMS of Ukraine	Kharkiv
Ukraine	Department of nervous system demyelization diseases of City Clinical Hospital	Kyiv
Ukraine	Odessa Regional Clinical Hospital	Odessa
Ukraine	Neurology department of Ukraine medical stomatological akademy	Poltava
Ukraine	Vinnytsya Regional Psychoneurological Hospital	Vinnytsya
United States	General Clinical Research Center 7A	Ann Arbor	Michigan
United States	MS Center of Atlanta	Atlanta	Georgia
United States	Neurological Research Center	Bennington	Vermont
United States	Patricia Fodor	Colorado Springs	Colorado
United States	Elkhardt Clinic	Elkhart	Indiana
United States	Sunrise Clinical Research	Hollywood	Florida
United States	MidAmerica Neuroscience Institute	Lenexa	Kansas
United States	OrthoArkansas, P. A.	Little Rock	Arkansas
United States	OrthoArkansas, P.A.	Little Rock	Arkansas
United States	Bhupesh Dihenia	Lubbock	Texas
United States	Winthrop University Hospital	Mineola	New York
United States	OSF Saint Francis Medical Center	Peoria	Illinois
United States	Virginia Commonwealth University Medical Center	Richmond	Virginia
United States	Medex Healthcare Research, Inc.	Saint Louis	Michigan
United States	Integra Clinical Research	San Antonio	Texas
United States	Springfield Neurology	Springfield	Massachusetts
United States	Meridien Research	Tampa	Florida
United States	Northern Michigan Neurology	Traverse City	Michigan
United States	Northwest NeuroSpecialists	Tucson	Arizona
United States	Crozer Chester Medical Center	Upland	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Impax Laboratories, LLC

Countries where clinical trial is conducted

United States,  Canada,  Estonia,  Latvia,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall mean changes from predose (baseline) in total Ashworth scores of the four lower extremity muscle groups (hip adductors, knee flexors, knee extensors, and plantar flexors) of both lower limbs over 12 hours assessed hourly after dosing		12 hours
Secondary	Duration of effect (improvement in Ashworth Scale) for IPX056		12 hours
Secondary	Establishment of relationships between baclofen plasma concentration with improvement in Ashworth Scale		12 hours